Michael Castagna is our Chief Executive Officer and serves on the Board of Directors for MannKind Corporation. Dr. Castagna has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. He joins MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs, and Vice President, Global Lifecycle Management. Prior to Amgen, Dr. Castagna, was Executive Director of Bristol-Myers Squibb’s Immunology franchise, where he served as co-lead to relaunch Orencia IV and launch Orencia SC, both rheumatoid arthritis drugs. Before BMS, Dr. Castagna was with Sandoz (Novartis) as Vice President and Division Head for Biopharmaceuticals, North America, where he established the US Biologics Business Unit and relaunched its lead product, Omnitrope, a human growth hormone. Prior to Sandoz, Dr. Castagna held a variety of positions with EMD (Merck), Serono, Pharmasset and DuPont Pharmaceuticals. Dr. Castagna serves on the board of directors of Pet Partners headquartered in Bellevue, Washington.
Dr. Castagna received his Bachelors of Science – Pharmacy degree from Philadelphia College of Pharmacy, his Doctor of Pharmacy from Massachusetts College of Pharmacy, and his MBA from the Wharton School of Business at the University of Pennsylvania.
Patrick McCauley is our Chief Commercial Officer for MannKind Corporation. Mr. McCauley has over 25 years of experience in the biopharmaceutical industry. He has spent the last twelve years at Astellas Pharma in a series of senior sales and compliance leadership roles of increasing responsibility. Prior to Astellas, Mr. McCauley was a member of the U.S. commercialization team and held a sales leadership role with Yamanouchi Pharma before the merger of Yamanouchi and Fujisawa Pharma to create Astellas in 2005. Before Astellas/Yamanouchi, Mr. McCauley spent thirteen years with DuPont Pharmaceuticals and one year with Bristol-Myers Squibb which acquired DuPont Pharmaceuticals in 2001. At DuPont and Bristol-Myers Squibb, Mr. McCauley held a series of leadership roles across the sales, contracting and pricing, and clinical areas. Throughout his various career moves, Mr. McCauley has developed deep commercial expertise serving both specialty and primary care healthcare providers. He received a MBA degree from the Kellogg School of Management at Northwestern University, a JD from the South Texas College of Law, and a BA in Economics from the University of Notre Dame.
David M. Kendall, MD, is the Chief Medical Officer for MannKind Corporation. In this role, he is responsible for leading MannKind’s scientific research, clinical development, regulatory, and medical affairs activity. Dr. Kendall’s career includes over 30 years of experience in diabetes and metabolism research, clinical management, research, and policy advocacy. Most recently, he served as Research Physician and Vice President of Global Medical Affairs for Lilly Diabetes, and led all medical affairs activities and guided research and development strategy across multiple geographies. During this time, Dr. Kendall worked to re-establish Lilly Diabetes as a world class medical organization — and added to his extensive experience with both injected and mealtime insulins, as well as devices and continuous glucose monitors. Prior to Eli Lilly, Dr. Kendall served as Chief Scientific and Medical Officer at the American Diabetes Association, where he was responsible for all medical affairs, medical education, research, outcomes, and medical policy activities. Earlier in his career, Dr. Kendall served as Medical Director at the International Diabetes Center, and the Park Nicollet Clinic, as well as at Amylin Pharmaceuticals. Dr. Kendall received his M.D. and completed his Post Graduate Medical Training at the University of Minnesota, and earned a B.A. in Biology from St. Olaf College.
Joseph Kocinsky is our Chief Technology Officer. Mr. Kocinsky has over 30 years’ experience in the pharmaceutical industry in technical operations and product development. Prior to joining MannKind in 2003, he held a variety of technical and management positions with increased responsibility at Schering-Plough. Mr. Kocinsky holds a bachelor’s degree in Chemical Engineering and a master’s degree in Biomedical Engineering from New Jersey Institute of Technology and a master’s degree in Business Administration from Seton Hall University.
Garrett Ingram is the Chief Marketing Officer for MannKind Corporation. Garrett comes to MannKind with a significant depth of experience in the biopharmaceutical industry and in diabetes marketing and market access. Most recently, Garrett served as Senior Vice President, Managed Markets for Dexcom, where she was responsible for developing long-term health outcomes and market access strategy for their portfolio of products. Before joining Dexcom, Garrett served as U.S. Country Head of Market Access at Sanofi, where she was responsible for all market access activities across four U.S. Business Units: Diabetes & Cardiovascular, General Medicines, Sanofi Genzyme Specialty Care, and Sanofi Pasteur. Prior to this, she held the position of Vice President, Market Access Strategy at Bristol Myers Squibb (BMS), where she led the access, reimbursement, patient affordability and emerging customer strategy teams across the portfolio of diabetes, rheumatoid arthritis, cardiovascular, oncology, immunology, neuroscience, and pipeline assets. Prior to BMS, she held various leadership roles for the commercial and medical organizations at Novo Nordisk, including Senior/Executive Director and Assistant Vice President, where she oversaw managed markets strategy, pricing and contracting, and health economics and outcomes research. Garrett received a Bachelor of Science degree from East Carolina University and a Master of Education in Community and Occupational Programs from the University of South Carolina.
Steven Binder is our Chief Financial Officer for MannKind Corporation. Mr. Binder has over 25 years of experience in the healthcare industry. He most recently spent four years at Stryker Corporation, a leading global medical technology company, where he served as Vice President and Chief Financial Officer for Stryker’s International Group, based in Singapore. Prior to Stryker, Mr. Binder served in a series of senior leadership roles at Bristol-Myers Squibb Company, an innovative global biopharmaceutical company. His last four positions at BMS were Vice President, Finance roles over different geographic operating units: United States (2012-2013), Europe (2008-2011), AsiaPacific (2005-2007), and Japan (2003-2005). Prior to his international experience, Mr. Binder served in three senior leadership roles for Oncology Therapeutics Network, a U.S. based independent subsidiary of BMS: Vice President, Strategic Development (2001-2003), Vice President, Customer Operations (2000-2001), and Chief Financial Officer (1997-2000). Before OTN, Mr. Binder progressed through three finance and accounting roles for BMS Worldwide Medicines Group after joining the company in 1992. Before BMS, he worked for Deloitte & Touche in a series of auditing roles with increasing responsibility over an eight year period beginning in 1984. Mr. Binder received a B.S. degree in Accounting and Business Administration from Muhlenberg College and is a Certified Public Accountant.
Rose Alinaya is the Senior Vice President, Investor Relations and Treasury, for MannKind Corporation. Ms. Alinaya has been our Vice President, Finance since March 2011 after serving as our Corporate Controller since June 2003 with responsibility for finance, accounting, tax, treasury, investor relations and risk management. Ms. Alinaya began her career at Deloitte & Touche LLP, graduating from California State University, Northridge with a B.S. degree in Accounting Information Systems. She is also a member of the American Institute of Certified Public Accountants and a member of the California Society of Certified Public Accountants.
David B. Thomson, Ph.D., J.D. has been our Corporate Vice President, General Counsel and Corporate Secretary since January 2002. Prior to joining us, he practiced corporate/commercial and securities law at the Toronto law firm of Davies Ward Phillips & Vineberg LLP. Earlier in his career, Dr. Thomson was a post-doctoral fellow at the Rockefeller University in New York. Dr. Thomson obtained his bachelor’s degree, master’s degree and Ph.D. degree from Queens University and obtained his J.D. degree from the University of Toronto.
Ms. Barton joined MannKind Corporation in March 2017 and is responsible for leading all aspects of our corporate and healthcare compliance programs. Ms. Barton brings broad, global compliance and ethics expertise to the role, having begun her compliance and ethics career at Winn-Dixie Stores, Incorporated before transitioning to roles in the pharmaceutical and medical device sector with Bausch + Lomb, Allergan, KYTHERA (Allergan) and Anacor (Pfizer). She has also held positions with Merrill Lynch and Janus, including an international appointment. A graduate of Syracuse University, Ms. Barton holds Bachelor’s degrees in Political Science and International Relations and is a Certified Compliance and Ethics Professional (CCEP) and Certified Information Privacy Professional (CIPP US/E).
Stuart A. Tross, Ph.D. is our Chief People Officer, with responsibilities for Human Resources, Information Technology, and West Coast Facilities. Dr. Tross joins MannKind with extensive experience in the life sciences industry. From 2006 to 2016 he served in roles of increasing responsibility at Amgen, the last three years as Senior Vice President and Chief Human Resources Officer responsible for Human Resources and security on a global basis. From 1998 to 2006 he served in a series of leadership roles at Bristol-Myers Squibb, the last three years as Vice President and Global Head of Human Resources for Mead Johnson Company. Stuart received a B.S. degree from Cornell University and M.S. and Ph.D. degrees in Industrial-Organization Psychology from the Georgia Institute of Technology.